Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance
Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance
复制标题
DOI：
10.1093/infdis/jix397
复制
发表时间：
2017-11-15
影响因子：
6.4
通讯作者：
Paredes, Roger
中科院分区：
文献类型：
--
作者：
Noguera-Julian, Marc;Edgil, Dianna;Paredes, Roger
需要高质量、简化且低成本的人类免疫缺陷病毒 (HIV) 耐药性测试，能够在个人、人群和规划层面提供及时、可操作的 HIV 耐药性数据，以应对新出现的耐药性 HIV 流行。嵌入自动化云计算分析环境中的下一代测序技术非常适合此类努力。虽然 NGS 比桑格测序可以降低成本，但自动化分析流程使分子实验室可以使用 NGS，无论现有的生物信息技能如何。它们还可以生成高度结构化的高质量数据，医疗保健官员和项目经理可以实时检查这些数据，以便及时采取公共卫生行动。在这里，我们讨论这种方法的机遇和挑战。
High-quality, simplified, and low-cost human immunodeficiency virus (HIV) drug resistance tests that are able to provide timely actionable HIV resistance data at individual, population, and programmatic levels are needed to confront the emerging drug-resistant HIV epidemic. Next-generation sequencing technologies embedded in automated cloud-computing analysis environments are ideally suited for such endeavor. Whereas NGS can reduce costs over Sanger sequencing, automated analysis pipelines make NGS accessible to molecular laboratories regardless of the available bioinformatic skills. They can also produce highly structured, high-quality data that could be examined by healthcare officials and program managers on a real-time basis to allow timely public health action. Here we discuss the opportunities and challenges of such an approach.